In Vitro and In Vivo Bactericidal and Antibiofilm Efficacy of Alpha Mangostin Against Staphylococcus aureus Persister Cells

被引:20
作者
Felix, LewisOscar [1 ]
Mishra, Biswajit [1 ]
Khader, Rajamohammed [1 ]
Ganesan, Narchonai [1 ]
Mylonakis, Eleftherios [1 ]
机构
[1] Brown Univ, Infect Dis Div, Alpert Med Sch, Providence, RI 02903 USA
基金
美国国家卫生研究院;
关键词
alpha mangostin; biofilm; persisters; Staphylococcus aureus; Galleria mellonella; GALLERIA-MELLONELLA; EFFLUX PUMPS; RESISTANCE; INFECTIONS; MODEL; MRSA; ANTIBIOTICS; INHIBITION; EXTRACTS; L;
D O I
10.3389/fcimb.2022.898794
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The formation of persister cells is associated with recalcitrance and infections. In this study, we examined the antimicrobial property of alpha mangostin, a natural xanthone molecule, against methicillin-resistant Staphylococcus aureus (MRSA) persisters and biofilm. The MIC of alpha mangostin against MRSA persisters was 2 mu g/ml, and activity was mediated by causing membrane permeabilization within 30 min of exposure. The membrane activity of alpha mangostin was further studied by fast-killing kinetics of MRSA persiste r cells and found that the compound exhibited 99.99% bactericidal activity within 30 min. Furthermore, alpha mangostin disrupted established MRSA biofilms and inhibited bacterial attachment as biofilm formation. Alpha mangostin down-regulated genes associated with the formation of persister cells and biofilms, such as norA, norB, dnaK, groE, and mepR, ranging from 2 to 4-folds. Alpha mangostin at 16 mu g/ml was non-toxic (> 95% cell survival) to liver-derived HepG2 and lung-derived A549 cells, similarly. Still, alpha mangostin exhibited 50% cell lysis of human RBC at 16 mu g/ml. Interestingly, alpha mangostin was effective in vivo at increasing the survival up to 75% (p<0.0001) of Galleria mellonella larvae infected with MRSA persister for 120 h. In conclusion, we report that alpha mangostin is active against MRSA persisters and biofilms, and these data further our understanding of the antistaphylococcal activity and toxicity of this natural compound.
引用
收藏
页数:14
相关论文
共 50 条
[1]   Vancomycin-Resistant Enterococci: A Review of Antimicrobial Resistance Mechanisms and Perspectives of Human and Animal Health [J].
Ahmed, Mohamed O. ;
Baptiste, Keith E. .
MICROBIAL DRUG RESISTANCE, 2018, 24 (05) :590-606
[2]   Metabolite-enabled eradication of bacterial persisters by aminoglycosides [J].
Allison, Kyle R. ;
Brynildsen, Mark P. ;
Collins, James J. .
NATURE, 2011, 473 (7346) :216-+
[3]   Antibiotic resistance: turning evolutionary principles into clinical reality [J].
Andersson, Dan, I ;
Balaban, Nathalie Q. ;
Baquero, Fernando ;
Courvalin, Patrice ;
Glaser, Philippe ;
Gophna, Uri ;
Kishony, Roy ;
Molin, Soren ;
Tonjum, Tone .
FEMS MICROBIOLOGY REVIEWS, 2020, 44 (02) :171-188
[4]   Novel Strategy for Biofilm Inhibition by Using Small Molecules Targeting Molecular Chaperone DnaK [J].
Arita-Moriok, Ken-ichi ;
Yamanaka, Kunitoshi ;
Mizunoe, Yoshimitsu ;
Ogura, Teru ;
Sugimoto, Shinya .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) :633-641
[5]   Bacterial persistence as a phenotypic switch [J].
Balaban, NQ ;
Merrin, J ;
Chait, R ;
Kowalik, L ;
Leibler, S .
SCIENCE, 2004, 305 (5690) :1622-1625
[6]   Distinguishing between resistance, tolerance and persistence to antibiotic treatment [J].
Brauner, Asher ;
Fridman, Ofer ;
Gefen, Orit ;
Balaban, Nathalie Q. .
NATURE REVIEWS MICROBIOLOGY, 2016, 14 (05) :320-330
[7]   Waves of resistance: Staphylococcus aureus in the antibiotic era [J].
Chambers, Henry F. ;
DeLeo, Frank R. .
NATURE REVIEWS MICROBIOLOGY, 2009, 7 (09) :629-641
[8]   A pursuit ofStaphylococcus aureuscontinues: a role of persister cells [J].
Chang, JuOae ;
Lee, Rho-Eun ;
Lee, Wonsik .
ARCHIVES OF PHARMACAL RESEARCH, 2020, 43 (06) :630-638
[9]   Rational design of α-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index [J].
Chen, YX ;
Mant, CT ;
Farmer, SW ;
Hancock, REW ;
Vasil, ML ;
Hodges, RS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (13) :12316-12329
[10]  
Clinical Laboratory Standards Institute, 2018, APPROVED STANDARD M0